Biosergen AS announced the appointment of Gunilla Ekström as new CEO. The company has developed a series of novel polyene macrolide antifungals with unique properties. The lead compound BSG005, which is currently in early preclinical development phase, has properties superior to those of the conventional antifungal therapy in terms of activity, toxicity and pharmacokinetics.

Gunilla Ekstr m holds an MD and PhD from Karolinska Institutet and is Associate Professor at Karolinska Institutet. She has over 20 years of experience from senior positions in the pharmaceutical industry, including as Global Product Director at AstraZeneca R&D and Senior Vice President at Orexo AB. She also serves as VP Operations of Karolinska Development and as Board Director of Lipidor AB and Pharmanest AB.

The former CEO, Nils Spids e, will remain in the company as senior advisor.